ClinicalTrials.gg
CompletedNCT00675103Updated Jun 28, 2011Results posted

Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients

A Phase 3 interventional study of pegloticase 8 mg i.v. in Chronic Gout Refractory to Conventional Therapy, sponsored by Savient Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.

Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
14th of 14
7 · median 93
Started
2008
the only one that year
Phase 3
4 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
4 of 14
Savient Pharmaceuticals

Among the 14 studies testing pegloticase in Gout, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 4th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry.

This study is limited to four study centers in the US.

03

Conditions studied

  • Chronic Gout Refractory to Conventional Therapy

Keywords

  • Gout
  • Gouty Arthritis
  • Anti-Gout preparations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous treatment in studies of pegloticase i.v.
  • Last exposure to pegloticase i.v. greater than one year prior to study entry
  • Symptomatic gout
  • Documented hyperuricemic (SUA ≥ 7 mg/dL)

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to Elitek® (rasburicase)
  • Unstable angina
  • Uncontrolled arrhythmia or hypertension
  • Non-compensated congestive heart failure
  • End stage renal disease requiring dialysis
  • Concomitant use of SUA lowering agents and use of other drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    pegloticase

    Drug: pegloticase 8 mg i.v.

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event Profile

    Number of participants reporting events

    Time frame: 6 months

Secondary outcomes

  1. Mean Plasma Uric Acid

    This endpoint assessed the change in mean PUA concentration from baseline after the first dose and after the third dose. Mean PUA was calculated from samples collected at 5 timepoints following each of those doses. For example, Mean PUA at Week 3 included 5 timepoints before dose 2 infusion.

    Time frame: Baseline, Week 3 and Week 7

07

Results

Posted Jun 28, 2011

Participant flow

Participant flow — Overall Study
MilestonePegloticase 8 mg Every 2 Wks
Started7
Completed4
Not completed3
Withdrew: Lack of efficacy2
Withdrew: Adverse event1

Outcome measures

PrimaryAdverse Event Profile

Number of participants reporting events

Time frame:
6 months
Reported as:
Number · Number of participants
Adverse Event Profile
Number of participantsPegloticase 8 mg Every 2 Wks
Adverse Events7
Serious Adverse Events2
SecondaryMean Plasma Uric Acid

This endpoint assessed the change in mean PUA concentration from baseline after the first dose and after the third dose. Mean PUA was calculated from samples collected at 5 timepoints following each of those doses. For example, Mean PUA at Week 3 included 5 timepoints before dose 2 infusion.

Time frame:
Baseline, Week 3 and Week 7
Reported as:
Mean · mg/dL
Mean Plasma Uric Acid
mg/dLPegloticase 8 mg Every 2 Wks
Baseline8.5 ± 1.21
Week 34.0 ± 2.63
Week 77.7 ± 5.61

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegloticase 8 mg Every 2 Wks——7/7 (100%)
Most frequent serious events
Most frequent serious events
EventPegloticase 8 mg Every 2 Wks
CellulitisInfections and infestations1/7
HyperglycaemiaMetabolism and nutrition disorders1/7
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPegloticase 8 mg Every 2 Wks
Gout (flare)Musculoskeletal and connective tissue disorders5/7
Infusion-Related ReactionGeneral disorders4/7
ArthralgiaMusculoskeletal and connective tissue disorders2/7
FatigueGeneral disorders1/7
Oedema PeripheralGeneral disorders1/7
Back PainMusculoskeletal and connective tissue disorders1/7
Shoulder PainMusculoskeletal and connective tissue disorders1/7
Upper Respiratory Tract InfectionInfections and infestations1/7
NauseaGeneral disorders1/7
VomitingGastrointestinal disorders1/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pegloticase 8 mg Every 2 Wks
<=18 years0
Between 18 and 65 years4
>=65 years3
Age Continuous
Age Continuous(years)Pegloticase 8 mg Every 2 Wks
Mean66.4 ± 8.77
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase 8 mg Every 2 Wks
Female1
Male6
Region of Enrollment
Region of Enrollment(participants)Pegloticase 8 mg Every 2 Wks
United States7
08

Study locations

4 sites
  • University of Chicago- Dept. Biological Services
    Chicago, Illinois 60637, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Portland Rheumatology Clinic, L.L.C.
    Lake Oswego, Oregon 97035, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jan 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2008
First posted
May 8, 2008
Start
May 2008
Primary completionActual
Jan 2009
CompletionActual
Apr 2009
Results first posted
Jun 28, 2011
Last update
Jun 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00675103
Lead sponsor
Savient Pharmaceuticals
First posted
May 8, 2008
Start date
May 2008
Primary completion
Jan 2009
Completion
Apr 2009
Results posted
Jun 28, 2011
Last update
Jun 28, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion